Freiburghaus, Tove
Pawlik, Daria
Oliveira Hauer, Kevin
Ossenkoppele, Rik
Strandberg, Olof
Leuzy, Antoine
Rittmo, Jonathan
Tremblay, Cécilia
Serrano, Geidy E.
Pontecorvo, Michael J.
Beach, Thomas G.
Smith, Ruben http://orcid.org/0000-0001-7147-0112
Hansson, Oskar
Funding for this research was provided by:
H2020 European Research Council (ADG-101096455)
Alzheimer's Association (ZEN24-1069572, SG-23-1061717)
GHR Foundation
Vetenskapsrådet (2022-00775)
ERA PerMed (ERAPERMED2021-184)
Knut och Alice Wallenbergs Stiftelse (2022-0231)
Strategic Research Area MultiPark
Alzheimerfonden (AF-980907, AF-939981)
Hjärnfonden (FO2021-0293)
Parkinsonfonden (1412/22)
Cure Alzheimer's Fund
Rönström Family Foundation
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Skånes universitetssjukhus (2020-O000028)
Regionalt Forskningsstöd (2022-1259, 2021-1013)
Kockska Foundation
Stiftelsen för Gamla Tjänarinnor
Swedish federal government under the ALF agreement (2022-Projekt0080, 2020-YF0020)
Lund University
Article History
Received: 14 June 2024
Revised: 5 September 2024
Accepted: 6 September 2024
First Online: 19 September 2024
Declarations
:
: TF, DP, KOH, OS, JR, and GES report no disclosures. AL serves as a consultant to Enigma Biomedical USA. CT has been supported by fellowships from the Canadian Institutes of Health Research (CIHR) and Quebec’s Health Research Funds (FRQS). RO has received research funding/support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, is an advisory board member for Asceneuron and a steering committee member for Bristol Myers Squibb. All the aforementioned has been paid to the institutions. MJP is a full-time employee of Eli Lilly and Company and own stock in the company. TGB is a consultant for Aprinoia Therapeutics, Vivid Genomics, and Avid Radiopharmaceutical, and is a scientific advisory board member for Vivid Genomics. RS has received a speaker fee from Roche. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens.